Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 303-313 , September 2009

Treatment strategies for CML

  • John M. Goldman (DM, FRCP, FMed Sci, Professor)

      Affiliations

    • Corresponding Author InformationTel.: +44 20 8383 3238.

References 

  1. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2–11
  2. Medical Research Council's Working Party for Therapeutic Trials in Leukaemia . Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Br Med J. 1968;(1):201–208
  3. Fefer A, Cheever MA, Thomnsas ED, et al. Disappearance of Ph1 positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300:333–337
  4. Goldman JM, Baughan ASJ, McCarthy DM, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet. 1982;(2):623–625
  5. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;(1):665–668
  6. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–1069
  7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J. Med. 1994;330:820–825
  8. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223–229
  9. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alfa: a study of complete cytogenetic responders. Blood. 2001;98:3074–3081
  10. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  11. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low- dose Ara-C for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  13. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood. 2008;112:76;[Abstract #186]
  14. Hochhaus A, O'Brien SG, Guilhot F, et al. Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;213:1054–1061
  15. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia in chronic phase: incidence of sustained responses in an intention to treat analysis. J Clin Oncol. 2008;26:3358–3363
  16. Kantarjian H, Talpaz M, O'Brien S, et al. High dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2004;103:2873–2878
  17. Guilhot F, Hughes TP, Cortes J, et al. Imatinib (IM) pharmacokinetics (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]). Blood. 2008;112:170;[abstr 447]
  18. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–916
  19. Marin D, Marktel S, Bua M, et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica. 2002;87:980–989
  20. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637–1647
  21. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432
  22. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood. 2007;109:58–60
  23. Mahon F-X, Huguet F, Guilhot F, et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from the French pilot study and first results of the multicentre ‘Stop Imatinib (STIM) study. Blood. 2008;112:76;[Abstract #187]
  24. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia. recommendations from an expert panel on behalf of the European leukemiaNet. Blood. 2006;108:1809–1820
  25. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of the European LeukemiaNet. J Clin Ocol, in press, doi:10.1200/JCO.2009.25.0779.
  26. Marin D, Goldman JM, Olavarria E, et al. Transient benefit only from increasing imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102:2702–2703
  27. Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113:2154–2160
  28. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112:516–518
  29. Milojkovic D, Nicholson M, Apperley JF, et al. Early prediction of success or failure using second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica, in press.
  30. Goldman JM, Druker B. Chronic myeloid leukemia: current treatment options. Blood. 2001;98:2039–2042
  31. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. Chronic leukemia working party of the European Group for Blood and Marrow Transplantation. Haematologica. 2006;91:513–521
  32. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant. 2008;42(Suppl. 2):S40–S46
  33. Garg RJ, Kantarjian HM, O'Brien S, et al. The use of nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors (TKI): long-term follow-up. Blood, in press, doi:10.1182/blood-2009-05-221531.
  34. Guilhot F, Mahon F-X, Guilhot J, et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): first results of the Phase III (SPIRIT) trial from the French CML Group (FI LMC). [Abstract #183] Blood. 2008;112:74
  35. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients with newly diagnosed previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase. Blood (ASH Annual Meeting Abstracts). 2008;112:[Abstract #446]
  36. Cortes J, O'Brien S, Jones D, et al. Dasatinib (SPRYCEL) in patients with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2006;112:[Abstract #2161]
  37. Goldman JM, Majhail NS, Klein J, et al. Myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase: incidence of relapse and late mortality in 5-year survivors, submitted for publication.
  38. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325
  39. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532–4539
  40. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–667
  41. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood. 2008;111:2843–2855
  42. Ottmann OG, Wassmann B. Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005;118–122
  43. Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program. 2007;435–443

PII: S1521-6926(09)00056-5

doi: 10.1016/j.beha.2009.08.001

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 303-313 , September 2009

Article Tools

* Image Usage & Resolution